Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Povorcitinib in Hepatic Impairment
NCT05624710Phase 1Completed
- Sponsor
- Incyte
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of povorcitinib, sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration and 1 more. Started Dec 2022; status: completed.
02
Drugs
povorcitinib
Beyond the preview
Go deeper on NCT05624710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624710.